Decitabine maintenance showed improved survival outcomes compared with observation alone, especially in FLT3-ITD–negative patients.
Retrospective analysis of large cohort of registry patients finds that TDT exerts no significant or clinically relevant effects on outcomes following intensive induction treatment with standard-dose cytarabine/daunorubicin (7+3) in newly diagnosed AML.
Combination therapy with FLAG-IDA plus venetoclax is safe and shows activity in newly diagnosed and relapsed/refractory AML.
Assessment of first-line hyper-CVAD plus ponatinib in patients with Ph+ ALL demonstrates high response and survival rates and long-term tolerability with adjusted dosing.
Venetoclax plus navitoclax (combined with chemotherapy) was well tolerated with promising efficacy in heavily pretreated patients with R/R ALL and LL.
Combination enasidenib plus azacitidine improved ORR and CR rates vs azacitidine alone in patients with newly diagnosed AML with IDH2 mutations who were ineligible for intensive chemotherapy.
In a retrospective study, older patients with R/R AML following first-line venetoclax plus a hypomethylating agent have poor OS outcomes.
High rates of MRD negativity observed in adult patients with Ph+ ALL treated with frontline dasatinib plus blinatumomab.
In children and young adults with intermediate- and high-risk first relapse of B-ALL, blinatumomab improved outcomes vs chemotherapy when administered as post-reinduction consolidation therapy prior to transplant.
Significant improvement in OS and RFS with CC-486 (oral azacitidine) maintenance therapy in patients with AML in first remission with intensive induction chemotherapy.